|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Receivables from collaborators | ||||||||||||||||||||
| Trade and other receivables, net | ||||||||||||||||||||
| Unbilled - collaboration and license revenue | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid research and development | ||||||||||||||||||||
| Prepaid manufacturing | ||||||||||||||||||||
| Prepaid and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Inventories, noncurrent portion | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Prepaid and other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation and employee benefits | ||||||||||||||||||||
| Accrued research and development | ||||||||||||||||||||
| Accrued and other liabilities | ||||||||||||||||||||
| Deferred revenue, current portion | ||||||||||||||||||||
| Current portion of notes payable and long-term royalty-based debt | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Notes payable, less current portion | ||||||||||||||||||||
| Long term royalty-based debt, less current portion | ||||||||||||||||||||
| Long term debt | ||||||||||||||||||||
| Long term obligation to collaborator, less current portion | ||||||||||||||||||||
| Deferred revenue, long-term | ||||||||||||||||||||
| Long-term portion of lease liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||
| Common stock, $0.001 par value, 150,000 shares authorized at March 31, 2020 and December 31, 2019; 78,484 shares and 77,925, shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total Portola stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
